STSA—(-81%)—fails again in acute migraine: https://www.globenewswire.com/news-release/2022/11/14/2554800/0/en/Satsuma-Pharmaceuticals-Announces-Topline-Results-from-SUMMIT-Phase-3-Trial-of-STS101-for-the-Acute-Treatment-of-Migraine.html STS101 was not statistically superior to placebo at two hours post-administration on the co-primary endpoints of freedom from pain and most bothersome symptom